NARI - Inari Medical Inc Stock Price, Fair Value and News

$43.95-0.50 (-1.12%)

Delayed as of 23 Oct 2024, 03:05 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NARI Price Action

Last 7 days

-0.9%

Last 30 days

1.8%

Last 90 days

-19.7%

Trailing 12 Months

-22.6%

NARI RSI Chart

NARI Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-45.4

Price/Sales (Trailing)

4.73

EV/EBITDA

-108.56

Price/Free Cashflow

130.3

NARI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NARI Fundamentals

NARI Revenue

Revenue (TTM)

547.5M

Rev. Growth (Yr)

22.53%

Rev. Growth (Qtr)

1.83%

NARI Earnings

Earnings (TTM)

-57.1M

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

-29.53%

NARI Profitability

EBT Margin

-6.41%

Return on Equity

-13.46%

Return on Assets

-8.48%

Free Cashflow Yield

0.77%

NARI Investor Care

Shares Dilution (1Y)

1.59%

Diluted EPS (TTM)

-0.99

NARI Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	520.7M	547.5M	0	0
2023	412.9M	439.1M	469.3M	493.6M
2022	306.3M	335.6M	358.9M	383.5M
2021	170.1M	208.2M	242.4M	277.0M
2020	71.1M	86.5M	110.9M	139.7M
2019	0	21.6M	36.4M	51.1M
2018	0	0	0	6.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Inari Medical Inc

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

CEO	Mr. Andrew J. Hykes
WEBSITE	inarimedical.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	1100

Inari Medical Inc Frequently Asked Questions

What is the ticker symbol for Inari Medical Inc? What does NARI stand for in stocks?

NARI is the stock ticker symbol of Inari Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inari Medical Inc (NARI)?

As of Tue Oct 22 2024, market cap of Inari Medical Inc is 2.59 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NARI stock?

You can check NARI's fair value in chart for subscribers.

Is Inari Medical Inc a good stock to buy?

The fair value guage provides a quick view whether NARI is over valued or under valued. Whether Inari Medical Inc is cheap or expensive depends on the assumptions which impact Inari Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NARI.

What is Inari Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, NARI's PE ratio (Price to Earnings) is -45.4 and Price to Sales (PS) ratio is 4.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NARI PE ratio will change depending on the future growth rate expectations of investors.